Nemaura Medical Strengthens Manufacturing Team in Preparation for SugarBEAT® Commercial Launch.
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive glucose trending device for use by persons with diabetes and pre-diabetics today announced it has expanded its manufacturing team with the appointments of Omar Farooq as Project Manager and David McLachlan as a Project Director, both of whom bring substantial expertise to the company.
Dr. Faz Chowdhury CEO of Nemaura Medical commented, ‘We are delighted to have Omar and David join our team, and are confident in their combined ability to support and guide the company’s manufacturing scale-up from initial launch in the United Kingdom, to a global launch in multiple territories.’
These appointments are intended to supplement Nemaura’s existing team of engineers, scientists and outsourced service providers as preparations continue for launch of sugarBEAT® in the coming months.
Omar is a chartered chemical engineer with 20 years of regulated industry experience across the full engineering lifecycle, including design, construction, commissioning, operation and process optimisation.
David will be directing the manufacturing and qualification strategy across multiple sites, to facilitate seamless transition into commercial launch and subsequently the scale up to support launches in multiple territories worldwide. David has an honours degree from Herriot Watt University, Edinburgh and over 25 years of experience in the healthcare industry. Most recently, he played a pivotal role in creating the manufacturing capability for the launch of a new blood glucose monitoring strip for a leading test strip manufacturer. This work included developing business cases for various manufacturing options, vendor selection and approval, and enhancing process throughput.
About Nemaura Medical, Inc.
Nemaura Medical Inc. (NASDAQ: NMRD), is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose trending device for use by persons with diabetes and pre-diabetics.
SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals over periods up to 24 hours.
SugarBEAT® can additionally be used by insulin using persons with diabetes as an adjunctive glucose monitoring device when calibrated by a finger stick reading.
For more information visit:
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts, and may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura Medical’s ongoing studies, including the safety and efficacy of Nemaura Medical’s sugarBEAT® system, the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell sugarBEAT®, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to sugarBEAT®. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the current year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.
Nemaura Medical Inc.
Chief Business Officer
The Ruth Group